Suppr超能文献

临床流行病学中现有数据源的使用:芬兰医疗保健登记处在阿尔茨海默病研究中的应用——阿尔茨海默病患者用药研究(MEDALZ-2005)。

Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research - the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study.

机构信息

Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland.

出版信息

Clin Epidemiol. 2013 Aug 7;5:277-85. doi: 10.2147/CLEP.S46622. eCollection 2013.

Abstract

Memory diseases are the most important determinant of health care service use and quality of life among older individuals. Adverse effects of medication are common among older people, but this age group is underrepresented in clinical trials. Finnish statutory health care and prescription registers, together with personal identification numbers (PINs) and a tax-supported public health plan covering all citizens provide excellent opportunities for epidemiological research. We used routinely collected data from the Finnish health care system to establish the Medication use among persons with Alzheimer's disease (MedAlz-2005) cohort. This cohort study will be used to assess medication use and its effects on health status and hospitalization among persons with Alzheimer's disease (Ad). The cohort includes all community-dwelling persons who had a clinically verified diagnosis of Ad, resided in Finland, and were alive on December 31, 2005 and a matched comparison person for each affected individual. data on purchased prescription medicines (1995-2009), inpatient hospital admissions (1972-2009), outpatient visits (1995-2009), details on diagnosed cancers (1972-2009), and mortality (until October 2010) are available for the whole cohort. This paper describes how this data can be utilized in etiological research and the assessment of health care service use, drug utilization, and associated adverse outcomes in a particularly vulnerable group that is often underrepresented in clinical trials.

摘要

记忆疾病是影响老年人医疗服务利用和生活质量的最重要决定因素。药物的不良反应在老年人中很常见,但这一年龄组在临床试验中的代表性不足。芬兰的法定医疗保健和处方登记系统,加上个人身份号码(PIN)和为所有公民提供的税收支持的公共卫生计划,为流行病学研究提供了极好的机会。我们使用芬兰医疗保健系统中常规收集的数据建立了患有阿尔茨海默病(MedAlz-2005)的人群的药物使用(MedAlz-2005)队列。这项队列研究将用于评估药物的使用及其对阿尔茨海默病(AD)患者健康状况和住院的影响。该队列包括所有居住在芬兰的、有临床确诊的 AD 诊断、居住在社区的人群,以及每个受影响个体的匹配对照者。从 1995 年至 2009 年购买的处方药、1972 年至 2009 年的住院治疗、1995 年至 2009 年的门诊就诊、1972 年至 2009 年诊断出的癌症的详细信息以及(截至 2010 年 10 月)的死亡率都可用于整个队列。本文描述了如何在病因研究和评估医疗服务利用、药物利用以及在临床试验中代表性不足的特定弱势群体中经常发生的不良后果方面利用这些数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/405e/3741080/266ef51b7d8e/clep-5-277Fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验